Current Infectious Disease Reports

, Volume 11, Issue 2, pp 113–119

Reactivation of hepatitis B: Pathogenesis and clinical implications

Article

Abstract

Chronic hepatitis B virus (HBV) is estimated to be present in 350 million people worldwide. One of its major complications is reactivation of dormant HBV, which is associated with significant morbidity and mortality. Although reactivation can occur spontaneously, the most common risk factor is initiation of immunosuppression. As the use of immunosuppressive therapy increases, the incidence of HBV reactivation is expected to rise. Screening with serologic markers for hepatitis B is recommended before initiating immunosuppressive therapy. In patients with no evidence of HBV infection, immunization is recommended. In chronic carriers, prophylactic antiviral treatment has been shown to decrease overall morbidity and mortality. Patients with inactive HBV should be monitored closely during immunosuppressive treatment with alanine transaminase and serum HBV-DNA levels and treated promptly if they develop HBV reactivation. Although HBV reactivation is a serious complication, it can be prevented with screening and prophylactic treatment.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lalazar G, Rund D, Shouval D: Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136: 699–712.PubMedCrossRefGoogle Scholar
  2. 2.
    Yeo W, Johnson P: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43: 209–220.PubMedCrossRefGoogle Scholar
  3. 3.
    Mindikoglu A, Regev A, Schiff E: Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and prevention. Clin Gastroenterol Hepatol 2006, 4: 1076–1081.PubMedCrossRefGoogle Scholar
  4. 4.
    Calabrese L, Zein N, Vassilopoulos D: Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic disease: assessment and preventive strategies. Ann Rheum Dis 2006, 65: 983–989.PubMedCrossRefGoogle Scholar
  5. 5.
    Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measure. J Viral Hepatitis 2004, 11: 97–107.CrossRefGoogle Scholar
  6. 6.
    Perrillo R: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically medicated liver disease. Gastroenterology 2001, 120: 1009–1022.PubMedCrossRefGoogle Scholar
  7. 7.
    Kohrt H, Ouyang D, Keeffe E: Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006, 24: 1003–1016.PubMedCrossRefGoogle Scholar
  8. 8.
    Esteve M, Saro C, Gonzalez-Huix, et al.: Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004, 53: 1363–1365.PubMedCrossRefGoogle Scholar
  9. 9.
    Tsai F, Hsieh S, Chen D, et al.: reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci 2006, 51: 1627–1632.PubMedCrossRefGoogle Scholar
  10. 10.
    Yeo W, Chan P, Zhong S, et al.: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62: 299–307.PubMedCrossRefGoogle Scholar
  11. 11.
    Nakamura Y, Motokura T, Fujita A, et al.: Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: survey in Japan 1987—1991. Cancer 1996, 78: 2210–2215.PubMedCrossRefGoogle Scholar
  12. 12.
    Cheng A, Hsiung C, Su I, et al.: Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBVCarriers with lymphoma. Hepatology 2003, 37: 1320–1328.PubMedCrossRefGoogle Scholar
  13. 13.
    Lau G, Leung Y, Fong D, et al.: High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002, 99: 2324–2330.PubMedCrossRefGoogle Scholar
  14. 14.
    Hui C, Cheung W, Au W, et al.: Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005, 54: 1597–1603.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhong S, Yeo W, Schroder C, et al.: High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004, 11: 55–59.PubMedCrossRefGoogle Scholar
  16. 16.
    Chu C, Liaw Y: Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007, 133: 1458–1465.PubMedCrossRefGoogle Scholar
  17. 17.
    Lau G, Yiu H, Fong D, et al.: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125: 1742–1749.PubMedCrossRefGoogle Scholar
  18. 18.
    Yu A, Cheung R, Keeffe E: Hepatitis B vaccines. Infect Dis Clin North Am 2006, 20: 27–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Shouval D: Hepatitis B vaccines. J Hepatol 2003, 39: S70–S76.PubMedCrossRefGoogle Scholar
  20. 20.
    Loomba R, Rowley A, Wesley R, et al.: Systemic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148: 519–528.PubMedGoogle Scholar
  21. 21.
    Saab S, Dong M, Joseph T, et al.: Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007, 46: 1049–1056.PubMedCrossRefGoogle Scholar
  22. 22.
    Martyak L, Taqavi E, Saab S: Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008, 28: 28–38.PubMedGoogle Scholar
  23. 23.
    Katz L, Fraser A, Gafter-Gvili A, et al.: Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systemic review and metaanalysis. J Viral Hepat 2008, 15: 89–102.PubMedGoogle Scholar
  24. 24.
    Dienstag J: Hepatitis B virus infection. N Engl J Med 2008, 359: 1486–1500.PubMedCrossRefGoogle Scholar
  25. 25.
    Yeo W, Chan P, Ho W, et al.: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004, 22: 927–934.PubMedCrossRefGoogle Scholar
  26. 26.
    Yeo W, Hui E, Chan A, et al.: Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005, 28: 379–384.PubMedCrossRefGoogle Scholar
  27. 27.
    Vassiliadis T, Garipidou V, Tziomalos K, et al.: Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy: a prospective case series. Am J Hematol 2005, 80: 197–203.PubMedCrossRefGoogle Scholar
  28. 28.
    Clark F, Drummond M, Chambers S, et al.: Successful treatment with lamivudine for fulminant reactivation hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma. Ann Oncol 1998, 9: 385–387.PubMedCrossRefGoogle Scholar
  29. 29.
    Papatheodoridis G, Dimou E, Papadimitropoulos V: Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002, 97: 1618–1628.PubMedCrossRefGoogle Scholar
  30. 30.
    Persico M, Marino F, Russo G, et al.: Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002, 99: 724–725.PubMedCrossRefGoogle Scholar
  31. 31.
    Liao C, Lee C, Wu H, et al.: Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin’s lymphoma. Br J Haematol 2002, 116: 166–169.PubMedCrossRefGoogle Scholar
  32. 32.
    Yeo W, Steinberg J, Tam J, et al.: Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999, 59: 263–269.PubMedCrossRefGoogle Scholar
  33. 33.
    Cainelli F, Longhi M, Concia E, et al.: Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 2001, 96: 1651–1652.PubMedCrossRefGoogle Scholar
  34. 34.
    Idilman R, Arat M, Soydan E, et al.: Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004, 11: 141–147.PubMedCrossRefGoogle Scholar
  35. 35.
    Idilman R: Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut 2006, 55: 1208–1209.PubMedGoogle Scholar
  36. 36.
    Lok A, Lai C, Leung N, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125: 1714–1722.PubMedCrossRefGoogle Scholar
  37. 37.
    Yen Y, Lu S, Chen C, et al.: Changes in serum hepatitis B e antigen (HbeAg) levels associated with the emergence of YMDD mutants in HbeAg non-seroconverted patients during lamivudine therapy. Liver Int 2007, 27: 1349–1355.PubMedGoogle Scholar
  38. 38.
    Leung N, Lai C, Chang T, et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33: 1527–1532.PubMedCrossRefGoogle Scholar
  39. 39.
    Lai C, Chein R, Leung N, et al.: A one year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 1998, 339: 61–68.PubMedCrossRefGoogle Scholar
  40. 40.
    Liaw Y, Leung N, Chang T, et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamivudine study group. Gastroenterology 2000, 119: 172–80.PubMedCrossRefGoogle Scholar
  41. 41.
    Chang T, Lai C, Chien R, et al.: Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004, 19: 1276–1282.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Case Medical CenterUniversity HospitalsClevelandUSA

Personalised recommendations